Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ABUS Arbutus Biopharma	$3.71 +1.1%	$3.33	$2.70 ▼ $4.72	$711.20M	1.01	832,525 shs	766,346 shs
CPRX Catalyst Pharmaceuticals	$20.59 +1.0%	$20.99	$19.00 ▼ $26.58	$2.52B	0.85	1.50 million shs	814,373 shs
KNSA Kiniksa Pharmaceuticals International	$33.49 0.0%	$30.41	$17.82 ▼ $34.55	$2.48B	0.2	517,503 shs	316,932 shs
RXRX Recursion Pharmaceuticals	$4.70 -3.3%	$5.44	$3.79 ▼ $12.36	$2.04B	0.91	17.60 million shs	15.05 million shs

These 7 Stocks Will Be Magnificent in 2025

Discover the next wave of investment opportunities with our report, 7 Stocks That Will Be Magnificent in 2025. Explore companies poised to replicate the growth, innovation, and value creation of the tech giants dominating today's markets.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ABUS Arbutus Biopharma	0.00%	+6.00%	+13.46%	+7.54%	-4.13%
CPRX Catalyst Pharmaceuticals	0.00%	-0.15%	-2.51%	-17.34%	+1.68%
KNSA Kiniksa Pharmaceuticals International	0.00%	+1.36%	+4.72%	+15.05%	+25.24%
RXRX Recursion Pharmaceuticals	0.00%	-2.69%	-17.25%	+7.06%	-35.44%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
ABUS Arbutus Biopharma	2.4544 of 5 stars	3.5	1.0	0.0	3.0	2.5	0.6
CPRX Catalyst Pharmaceuticals	4.8314 of 5 stars	3.6	1.0	3.9	2.7	3.3	3.8
KNSA Kiniksa Pharmaceuticals International	2.1939 of 5 stars	2.5	3.0	0.0	2.2	3.3	0.6
RXRX Recursion Pharmaceuticals	1.9237 of 5 stars	3.2	1.0	0.0	2.2	2.5	0.6

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
ABUS Arbutus Biopharma	3.00	Buy	$5.50	48.25% Upside
CPRX Catalyst Pharmaceuticals	3.13	Buy	$33.20	61.24% Upside
KNSA Kiniksa Pharmaceuticals International	3.00	Buy	$41.17	22.92% Upside
RXRX Recursion Pharmaceuticals	2.33	Hold	$7.00	48.94% Upside

Current Analyst Ratings Breakdown

Latest ABUS, RXRX, CPRX, and KNSA Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
8/19/2025	CPRX Catalyst Pharmaceuticals	Zacks Research Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Strong-Buy ➝ Hold
8/11/2025	ABUS Arbutus Biopharma	Chardan Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$5.00
7/29/2025	KNSA Kiniksa Pharmaceuticals International	Jefferies Financial Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Buy ➝ Buy	$45.00 ➝ $54.00
7/21/2025	KNSA Kiniksa Pharmaceuticals International	Wedbush Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Outperform	$36.00
7/9/2025	KNSA Kiniksa Pharmaceuticals International	Wells Fargo & Company Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Overweight ➝ Overweight	$30.00 ➝ $42.00
7/8/2025	RXRX Recursion Pharmaceuticals	Needham & Company LLC Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$8.00
7/3/2025	RXRX Recursion Pharmaceuticals	Morgan Stanley Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Equal Weight	$5.00
6/16/2025	RXRX Recursion Pharmaceuticals	Morgan Stanley Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Equal Weight ➝ Equal Weight	$8.00 ➝ $5.00
6/5/2025	CPRX Catalyst Pharmaceuticals	Cantor Fitzgerald Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Strong-Buy

(Data available from 9/2/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
ABUS Arbutus Biopharma	$6.17M	115.27	N/A	N/A	$0.51 per share	7.27
CPRX Catalyst Pharmaceuticals	$491.73M	5.12	$2.45 per share	8.42	$6.10 per share	3.38
KNSA Kiniksa Pharmaceuticals International	$423.24M	5.86	N/A	N/A	$6.60 per share	5.07
RXRX Recursion Pharmaceuticals	$58.84M	34.68	N/A	N/A	$2.61 per share	1.80

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
ABUS Arbutus Biopharma	-$69.92M	-$0.29	N/A	N/A	N/A	-352.24%	-59.28%	-44.11%	11/5/2025 (Estimated)
CPRX Catalyst Pharmaceuticals	$163.89M	$1.65	12.48	9.67	0.84	37.36%	40.78%	35.36%	11/5/2025 (Estimated)
KNSA Kiniksa Pharmaceuticals International	-$43.19M	$0.04	837.46	133.96	N/A	0.90%	1.05%	0.80%	11/4/2025 (Estimated)
RXRX Recursion Pharmaceuticals	-$463.66M	-$1.78	N/A	N/A	N/A	-1,004.91%	-76.09%	-54.29%	11/5/2025 (Estimated)

Latest ABUS, RXRX, CPRX, and KNSA Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/6/2025	Q2 2025	ABUS Arbutus Biopharma	-$0.02	$0.01	+$0.03	$0.01	$2.21 million	$10.74 million
8/5/2025	Q2 2025	RXRX Recursion Pharmaceuticals	-$0.35	-$0.41	-$0.06	-$0.41	$15.38 million	$19.10 million
7/29/2025	Q2 2025	KNSA Kiniksa Pharmaceuticals International	$0.18	$0.23	+$0.05	$0.23	$145.21 million	$156.80 million

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
ABUS Arbutus Biopharma	N/A	N/A	N/A	N/A	N/A
CPRX Catalyst Pharmaceuticals	N/A	N/A	N/A	N/A	N/A
KNSA Kiniksa Pharmaceuticals International	N/A	N/A	N/A	N/A	N/A
RXRX Recursion Pharmaceuticals	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
ABUS Arbutus Biopharma	N/A	20.53	20.53
CPRX Catalyst Pharmaceuticals	N/A	6.71	6.55
KNSA Kiniksa Pharmaceuticals International	N/A	3.57	3.16
RXRX Recursion Pharmaceuticals	0.02	3.58	3.58

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
ABUS Arbutus Biopharma	43.79%
CPRX Catalyst Pharmaceuticals	79.22%
KNSA Kiniksa Pharmaceuticals International	53.95%
RXRX Recursion Pharmaceuticals	89.06%

Insider Ownership

Company	Insider Ownership
ABUS Arbutus Biopharma	20.30%
CPRX Catalyst Pharmaceuticals	10.40%
KNSA Kiniksa Pharmaceuticals International	53.48%
RXRX Recursion Pharmaceuticals	8.43%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
ABUS Arbutus Biopharma	90	191.70 million	152.78 million	Optionable
CPRX Catalyst Pharmaceuticals	80	122.39 million	109.66 million	Optionable
KNSA Kiniksa Pharmaceuticals International	220	74.11 million	34.48 million	Optionable
RXRX Recursion Pharmaceuticals	400	434.15 million	397.55 million	Optionable

ABUS, RXRX, CPRX, and KNSA Headlines

Recent News About These Companies

Jump Financial LLC Increases Position in Recursion Pharmaceuticals, Inc. $RXRX

August 29, 2025 | marketbeat.com

Recursion Pharmaceuticals, Inc. (RXRX) Expands Rare Disease Pipeline with REV102 Acquisition

August 28, 2025 | insidermonkey.com

Recursion to Participate in Upcoming Investor Conferences

August 27, 2025 | globenewswire.com

Contrasting Recursion Pharmaceuticals (NASDAQ:RXRX) and Organogenesis (NASDAQ:ORGO)

August 27, 2025 | americanbankingnews.com

1,912,620 Shares in Recursion Pharmaceuticals, Inc. $RXRX Purchased by Nuveen LLC

August 25, 2025 | marketbeat.com

Needham Maintains Buy Rating on Recursion (RXRX)

August 24, 2025 | msn.com

The Next Big Thing: 2 AI-Powered Healthcare Stocks Ready to Explode

August 23, 2025 | fool.com

Recursion Pharmaceuticals, Inc. $RXRX Stock Position Reduced by Vanguard Group Inc.

August 23, 2025 | marketbeat.com

Why Recursion Pharmaceuticals Stock Caught a Cold This Week

August 22, 2025 | fool.com

Recursion Pharmaceuticals (RXRX) Sees Sales And Revenue Growth In Q2 2025

August 22, 2025 | finance.yahoo.com

Insider Selling: Recursion Pharmaceuticals (NASDAQ:RXRX) Insider Sells 36,599 Shares of Stock

August 21, 2025 | marketbeat.com

Recursion Pharmaceuticals (RXRX) Drops on 3rd Day as Company Execs Dispose of Shares

August 21, 2025 | insidermonkey.com

Recursion Pharmaceuticals (NASDAQ:RXRX) Shares Down 5.3% - Here's Why

August 20, 2025 | marketbeat.com

Recursion Pharmaceuticals (NASDAQ:RXRX) Insider Najat Khan Sells 36,599 Shares

August 20, 2025 | insidertrades.com

EverSource Wealth Advisors LLC Raises Stake in Recursion Pharmaceuticals, Inc. $RXRX

August 20, 2025 | marketbeat.com

LPL Financial LLC Purchases 57,305 Shares of Recursion Pharmaceuticals, Inc. $RXRX

August 20, 2025 | marketbeat.com

Recursion: "Hold" Rating Based On Initial REC-4881 FAP Treatment Data

August 19, 2025 | seekingalpha.com

Liontrust Investment Partners LLP Lowers Stake in Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX)

August 18, 2025 | marketbeat.com

Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) Shares Sold by Vestmark Advisory Solutions Inc.

August 18, 2025 | marketbeat.com

Recursion Pharmaceuticals (RXRX) Expands AI Drug Discovery Pipeline with New Clinical Candid

August 17, 2025 | insidermonkey.com

Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) Given Consensus Recommendation of "Hold" by Brokerages

August 14, 2025 | marketbeat.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

ABUS, RXRX, CPRX, and KNSA Company Descriptions

Arbutus Biopharma NASDAQ:ABUS

$3.71 +0.04 (+1.09%)

Closing price 08/29/2025 04:00 PM Eastern

Extended Trading

$3.72 +0.00 (+0.13%)

As of 08/29/2025 07:08 PM Eastern

Arbutus Biopharma Corporation, a biopharmaceutical company, develops novel therapeutics for chronic Hepatitis B virus (HBV) infection in the United States. Its HBV product pipeline consists of imdusiran (AB-729), a proprietary subcutaneously-delivered RNAi therapeutic product candidate that suppresses all HBV antigens, including HBsAg expression. The company's research and development programs include AB-101, an oral PD-L1 inhibitor to reawaken patients' HBV-specific immune system; and small molecule antiviral medicines to treat coronaviruses, including COVID-19. It has licensing agreements with Gritstone Oncology, Inc; Alnylam Pharmaceuticals, Inc.; Qilu Pharmaceuticals Co, Ltd; Assembly Biosciences, Inc.; Acuitas Therapeutics, Inc.; and Antios Therapeutics, Inc. Arbutus Biopharma Corporation also has a clinical collaboration agreement with Barinthus Biotherapeutics plc to evaluate VTP-300. The company was formerly known as Tekmira Pharmaceuticals Corporation and changed its name to Arbutus Biopharma Corporation in July 2015. Arbutus Biopharma Corporation is headquartered in Warminster, Pennsylvania.

Catalyst Pharmaceuticals NASDAQ:CPRX

$20.59 +0.21 (+1.03%)

Closing price 08/29/2025 04:00 PM Eastern

Extended Trading

$20.43 -0.16 (-0.78%)

As of 08/29/2025 07:56 PM Eastern

Catalyst Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies for people with rare debilitating, chronic neuromuscular, and neurological diseases in the United States. It offers Firdapse, an amifampridine phosphate tablets for the treatment of patients with lambert-eaton myasthenic syndrome (LEMS); and Ruzurgi for the treatment of pediatric LEMS patients. The company develops Firdapse for the treatment of MuSK antibody positive myasthenia gravis and spinal muscular atrophy type. It has license agreements with BioMarin Pharmaceutical Inc.; and collaboration and license agreement with Endo Ventures Limited for the development and commercialization of generic Sabril tablets. The company was founded in 2002 and is based in Coral Gables, Florida.

Kiniksa Pharmaceuticals International NASDAQ:KNSA

$33.49 -0.01 (-0.03%)

Closing price 08/29/2025 04:00 PM Eastern

Extended Trading

$33.50 +0.01 (+0.03%)

As of 08/29/2025 06:42 PM Eastern

Kiniksa Pharmaceuticals, Ltd., a biopharmaceutical company, focuses on discovering, acquiring, developing, and commercializing therapeutic medicines for patients suffering from debilitating diseases with significant unmet medical needs worldwide. Its product candidates include ARCALYST, an interleukin-1alpha and interleukin-1beta, for the treatment of recurrent pericarditis, which is an inflammatory cardiovascular disease; Mavrilimumab, a monoclonal antibody inhibitor that completed Phase II clinical trials for the treatment of giant cell arteritis; Vixarelimab, a monoclonal antibody, that is in Phase 2b clinical trial for the treatment of prurigo nodularis, a chronic inflammatory skin condition; and KPL-404, a monoclonal antibody inhibitor of the CD40- CD154 interaction, a T-cell co-stimulatory signal critical for B-cell maturation, immunoglobulin class switching, and type 1 immune response. The company was incorporated in 2015 and is based in Hamilton, Bermuda.

Recursion Pharmaceuticals NASDAQ:RXRX

$4.70 -0.16 (-3.29%)

Closing price 08/29/2025 04:00 PM Eastern

Extended Trading

$4.69 -0.01 (-0.21%)

As of 08/29/2025 07:59 PM Eastern

Recursion Pharmaceuticals, Inc. operates as a clinical-stage biotechnology company, engages in the decoding biology by integrating technological innovations across biology, chemistry, automation, data science, and engineering to industrialize drug discovery. The company develops REC-994, which is in Phase 2 clinical trial to treat cerebral cavernous malformation; REC-2282, which is in Phase 2/3 clinical trial for the treatment of neurofibromatosis type 2; REC-4881, which is in Phase 1b/2 clinical trial to treat familial adenomatous polyposis; REC-3964, which is in Phase 1 clinical trial to treat Clostridioides difficile infection; and REC-4881, which is in Phase 2 clinical trial to treat AXIN1 or APC mutant cancers. Its preclinical stage product includes RBM39 to treat HR-proficient ovarian cancer. The company has collaboration and agreement with Bayer AG; the University of Utah Research Foundation; Ohio State Innovation Foundation; Roche & Genentech; and Takeda Pharmaceutical Company Limited. Recursion Pharmaceuticals, Inc. was incorporated in 2013 and is headquartered in Salt Lake City, Utah.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time